Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Thermo Fisher Scientific buys Patheon for $7.2 billion

Patheon will facilitate Thermo Fisher's entry into the high-growth $40-billion CDMO market

BS B2B Bureau  |  Waltham, Massachusetts 

Patheon lab

Inc has acquired NV, the Netherlands-based global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, for $7.2 billion, which includes the assumption of approximately $ 2 billion of net debt. 

provides comprehensive, integrated and highly customisable solutions as well as the expertise to help biopharmaceutical companies of all sizes satisfy complex development and manufacturing needs. It is a leader in the high-growth, $40 billion (contract development and manufacturing organisation) market, which is fuelled by growing customer demand for end-to-end solutions, flexible and scalable capacity, and regulatory expertise. has an extensive network of state-of-the-art facilities primarily in North America and Europe, and approximately 9,000 professionals worldwide. The company generated 2016 revenue of approximately $1.9 billion and will become part of Thermo Fisher’s laboratory products and services segment.

“Patheon’s development and manufacturing capabilities are an excellent complement to our industry-leading offering for the biopharma market. Our combined capabilities will enhance our unique value proposition for these customers, create significant value for our shareholders and further accelerate our company’s growth,” said Marc N Casper, president and chief executive officer of

will facilitate Thermo Fisher’s entry into the attractive, high-growth market. serves a large, fragmented market growing in the mid-single to high-single digits, which is fuelled by strong demand for outsourcing services that allow customers to simplify their supply-chain networks. By offering both small- and large-molecule development and manufacturing solutions, the company helps customers reduce the time and cost of delivering medicines to market. has invested significantly to become a scale player in the market and extend its leadership position.

Combination will significantly strengthen Thermo Fisher’s unique value proposition for pharmaceutical and biotech customers by adding highly complementary services. Thermo Fisher is the leading supplier to the biopharmaceutical industry, supporting research, clinical trials and production. It has become a trusted outsourcing partner by providing clinical trials logistics services over the past decade. Combining these capabilities with Patheon’s services will allow Thermo Fisher to be a stronger partner for pharmaceutical and biotech customers.

The combined company’s extensive and deep relationships in the biopharma industry will enable significant cross-selling opportunities. For example, having development and manufacturing capabilities as well as bioproduction technologies in one company will allow Thermo Fisher to offer a more comprehensive portfolio to gain share with these customers.

RECOMMENDED FOR YOU

Thermo Fisher Scientific buys Patheon for $7.2 billion

Patheon will facilitate Thermo Fisher's entry into the high-growth $40-billion CDMO market

Patheon will facilitate Thermo Fisher's entry into the high-growth $40-billion CDMO market
Inc has acquired NV, the Netherlands-based global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, for $7.2 billion, which includes the assumption of approximately $ 2 billion of net debt. 

provides comprehensive, integrated and highly customisable solutions as well as the expertise to help biopharmaceutical companies of all sizes satisfy complex development and manufacturing needs. It is a leader in the high-growth, $40 billion (contract development and manufacturing organisation) market, which is fuelled by growing customer demand for end-to-end solutions, flexible and scalable capacity, and regulatory expertise. has an extensive network of state-of-the-art facilities primarily in North America and Europe, and approximately 9,000 professionals worldwide. The company generated 2016 revenue of approximately $1.9 billion and will become part of Thermo Fisher’s laboratory products and services segment.

“Patheon’s development and manufacturing capabilities are an excellent complement to our industry-leading offering for the biopharma market. Our combined capabilities will enhance our unique value proposition for these customers, create significant value for our shareholders and further accelerate our company’s growth,” said Marc N Casper, president and chief executive officer of

will facilitate Thermo Fisher’s entry into the attractive, high-growth market. serves a large, fragmented market growing in the mid-single to high-single digits, which is fuelled by strong demand for outsourcing services that allow customers to simplify their supply-chain networks. By offering both small- and large-molecule development and manufacturing solutions, the company helps customers reduce the time and cost of delivering medicines to market. has invested significantly to become a scale player in the market and extend its leadership position.

Combination will significantly strengthen Thermo Fisher’s unique value proposition for pharmaceutical and biotech customers by adding highly complementary services. Thermo Fisher is the leading supplier to the biopharmaceutical industry, supporting research, clinical trials and production. It has become a trusted outsourcing partner by providing clinical trials logistics services over the past decade. Combining these capabilities with Patheon’s services will allow Thermo Fisher to be a stronger partner for pharmaceutical and biotech customers.

The combined company’s extensive and deep relationships in the biopharma industry will enable significant cross-selling opportunities. For example, having development and manufacturing capabilities as well as bioproduction technologies in one company will allow Thermo Fisher to offer a more comprehensive portfolio to gain share with these customers.

image
Business Standard
177 22

Thermo Fisher Scientific buys Patheon for $7.2 billion

Patheon will facilitate Thermo Fisher's entry into the high-growth $40-billion CDMO market

Inc has acquired NV, the Netherlands-based global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, for $7.2 billion, which includes the assumption of approximately $ 2 billion of net debt. 

provides comprehensive, integrated and highly customisable solutions as well as the expertise to help biopharmaceutical companies of all sizes satisfy complex development and manufacturing needs. It is a leader in the high-growth, $40 billion (contract development and manufacturing organisation) market, which is fuelled by growing customer demand for end-to-end solutions, flexible and scalable capacity, and regulatory expertise. has an extensive network of state-of-the-art facilities primarily in North America and Europe, and approximately 9,000 professionals worldwide. The company generated 2016 revenue of approximately $1.9 billion and will become part of Thermo Fisher’s laboratory products and services segment.

“Patheon’s development and manufacturing capabilities are an excellent complement to our industry-leading offering for the biopharma market. Our combined capabilities will enhance our unique value proposition for these customers, create significant value for our shareholders and further accelerate our company’s growth,” said Marc N Casper, president and chief executive officer of

will facilitate Thermo Fisher’s entry into the attractive, high-growth market. serves a large, fragmented market growing in the mid-single to high-single digits, which is fuelled by strong demand for outsourcing services that allow customers to simplify their supply-chain networks. By offering both small- and large-molecule development and manufacturing solutions, the company helps customers reduce the time and cost of delivering medicines to market. has invested significantly to become a scale player in the market and extend its leadership position.

Combination will significantly strengthen Thermo Fisher’s unique value proposition for pharmaceutical and biotech customers by adding highly complementary services. Thermo Fisher is the leading supplier to the biopharmaceutical industry, supporting research, clinical trials and production. It has become a trusted outsourcing partner by providing clinical trials logistics services over the past decade. Combining these capabilities with Patheon’s services will allow Thermo Fisher to be a stronger partner for pharmaceutical and biotech customers.

The combined company’s extensive and deep relationships in the biopharma industry will enable significant cross-selling opportunities. For example, having development and manufacturing capabilities as well as bioproduction technologies in one company will allow Thermo Fisher to offer a more comprehensive portfolio to gain share with these customers.

image
Business Standard
177 22